CTOs on the Move

LeMaitre Vascular, Inc.

www.lemaitre.com

 
LeMaitre Vascular, Inc. (LeMaitre Vascular) is a provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Patterson Medical

Patterson Medical is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PresenceLearning

PresenceLearning is the leading provider of online special education services for early intervention and K-12 students in the United States. We provide “anytime, anywhere” access to a network of more than 700 fully licensed, highly qualified clinicians who work face-to-face with students via live videoconferencing using our proprietary platform and instructional activities. Since our founding in 2009, we have delivered more than 1,000,000 sessions of teletherapy to hundreds of school districts, charter schools, and virtual school organizations across the United States. And we`re not stopping there. The shortage of Speech-Language Pathologists (SLPs), Occupational Therapists (OTs), and Mental Health Professionals (MHPs) is reaching crisis proportions, innovative modes of delivery have become essential for providing access to therapeutic services. Our dedicated team of employees is committed to seeing children thrive via the growing online therapy revolution.

La Mesa Healthcare Center

La Mesa Healthcare Center is a La Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fitzgerald Industries International

Fitzgerald Industries International is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.